Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia.
Rimonabant, a selective cannabinoid-1 (CB1) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of rimonabant in Asian population. A total of 643 patients (BMI 25 kg/m(2) or greater without diabetes) from China, Republic of Korea, and Taiwan were prescribed a hypocaloric diet (600 kcal/day deficit) and randomized to rimonabant 20 mg (n = 318) or placebo (n = 325) for 9months. The primary efficacy variable was weight change from baseline after 9 months of treatment. Results showed that rimonabant group lost more weight than placebo, (LSM ± SEM of -4.7 ± 0.3 kg vs. -1.7 ± 0.3 kg, P < .0001). The 5% and 10% responders were 2 or 3 folds more in the rimonabant group (53.0% vs. 20.0% and 21.5% vs. 5.7%, resp.) (P < .0001). Rimonabant also significantly increased HDL-cholesterol, decreased triglycerides and waist circumference,by 7.1%, 10.6%, and 2.8 cm, respectively (P < .0001). This study confirmed the comparable efficacy and safety profile of rimonabant in Asian population to Caucasians. Owing to the recent suspension of all the CB1 antagonists off the pharmaceutical market for weight reduction in Europe and USA, a perspective in drug discovery for intervening peripheral CB1 receptor in the management of obesity is discussed.
Department of Endocrinology, Chinese PLA, General Hospital, No. 28, Fuxing Road, Beijing 100853, China.
Changyu
C
Pan
Hyung Joon
HJ
Yoo
Low-Tone
LT
Ho
Lancet. 2004 Jan 10;363(9403):157-63
14726171
Am J Clin Nutr. 2004 Jan;79(1):31-9
14684394
Bioorg Med Chem Lett. 2010 Jan 15;20(2):453-7
20015647
Endocrinology. 2008 May;149(5):2557-66
18276749
BMJ. 2006 Aug 19;333(7564):362-3
16916811
J Clin Endocrinol Metab. 2000 Mar;85(3):1151-8
10720054
Hypertens Res. 2008 Jul;31(7):1385-90
18957809
Mol Pharmacol. 2007 Jun;71(6):1445-56
17327463
Circulation. 2007 Oct 23;116(17):1942-51
17965405
J Neuroendocrinol. 2008 May;20 Suppl 1:139-46
18426513
Obes Rev. 2009 Jan;10(1):58-67
18721231
Obes Rev. 2005 Nov;6(4):271-4
16246212
J Clin Invest. 2010 Aug;120(8):2953-66
20664173
Cell Metab. 2010 Apr 7;11(4):273-85
20374960
Hepatology. 2007 Jul;46(1):122-9
17526015
Arterioscler Thromb Vasc Biol. 2006 May;26(5):968-76
16627822
J Med Chem. 2009 Jul 23;52(14):4496-510
19530697
Vasc Health Risk Manag. 2007;3(2):181-90
17580728
Lancet. 2007 Nov 17;370(9600):1706-13
18022033
Curr Opin Pharmacol. 2007 Dec;7(6):575-82
17904903
Chin Med J (Engl). 2008 Jun 5;121(11):1043-50
18706257
Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65
19249987
J Biol Chem. 1996 Mar 22;271(12):6941-6
8636122
Int J Obes Relat Metab Disord. 2003 Feb;27(2):253-9
12587007
Int J Cancer. 2008 Oct 15;123(8):1892-6
18651571
Am J Psychiatry. 2007 Jul;164(7):1035-43
17606655
Obes Rev. 2005 May;6(2):117-21
15836462
N Engl J Med. 2005 Nov 17;353(20):2121-34
16291982
JAMA. 2006 Feb 15;295(7):761-75
16478899
Pharmacol Res. 2009 Aug;60(2):77-84
19559360
Int J Obes Relat Metab Disord. 1993 Apr;17(4):187-96
8387967
Obes Res. 2004 Mar;12(3):440-1
15044659
Bioorg Med Chem Lett. 2009 Feb 1;19(3):639-43
19128970
Obes Res. 2004 Feb;12(2):180-6
14981209
Lancet. 2005 Apr 16-22;365(9468):1389-97
15836887
Obes Res. 2004 Mar;12(3):445-53
15044661